Novartis receives FDA approval for new radioligand therapy facility in Indianapolis

Novartis announced FDA approval for commercial manufacturing of Pluvicto at its new 70,000-square foot radioligand therapy manufacturing facility in Indianapolis, Indiana. The facility is the company's largest and most advanced RLT site, increasing production capacity to 250,000 doses in 2024.

“Adding a second US RLT facility, our largest and most advanced yet, into our manufacturing network underscores our commitment to ensure a consistent and reliable experience for patients”novartis.com

• 1 source
• novartis.comNovartis expands production of Pluvicto™ with addition ...Jan 5, 2024

Summarized from public sources; check the original articles before acting on it.